PTC Therapeutics (PTCT) to Release Earnings on Thursday

PTC Therapeutics (NASDAQ:PTCT) will post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect PTC Therapeutics to post earnings of ($1.52) per share for the quarter. PTC Therapeutics has set its FY 2024 guidance at EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.16). The company had revenue of $186.70 million during the quarter, compared to analyst estimates of $192.12 million. On average, analysts expect PTC Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

PTC Therapeutics Price Performance

NASDAQ PTCT opened at $40.66 on Thursday. PTC Therapeutics has a one year low of $17.53 and a one year high of $43.40. The business has a 50 day simple moving average of $36.31 and a 200 day simple moving average of $34.21. The stock has a market capitalization of $3.13 billion, a P/E ratio of -6.57 and a beta of 0.65.

Analysts Set New Price Targets

Several equities research analysts have recently commented on PTCT shares. Raymond James started coverage on PTC Therapeutics in a report on Thursday, October 10th. They set a “market perform” rating for the company. Royal Bank of Canada boosted their price objective on PTC Therapeutics from $32.00 to $34.00 and gave the company a “sector perform” rating in a report on Friday, October 4th. Barclays boosted their price objective on PTC Therapeutics from $25.00 to $31.00 and gave the company an “equal weight” rating in a report on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and set a $64.00 price objective on shares of PTC Therapeutics in a report on Tuesday, September 17th. Finally, Baird R W upgraded PTC Therapeutics to a “strong-buy” rating in a report on Wednesday, September 4th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $40.08.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.